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Abstract
Naturally acquired blood-stage infections of the malaria parasite Plasmodium falciparum typically harbour multiple haploid
clones. The apparent number of clones observed in any single infection depends on the diversity of the polymorphic
markers used for the analysis, and the relative abundance of rare clones, which frequently fail to be detected among PCR
products derived from numerically dominant clones. However, minority clones are of clinical interest as they may harbour
genes conferring drug resistance, leading to enhanced survival after treatment and the possibility of subsequent
therapeutic failure. We deployed new generation sequencing to derive genome data for five non-propagated parasite
isolates taken directly from 4 different patients treated for clinical malaria in a UK hospital. Analysis of depth of coverage and
length of sequence intervals between paired reads identified both previously described and novel gene deletions and
amplifications. Full-length sequence data was extracted for 6 loci considered to be under selection by antimalarial drugs,
and both known and previously unknown amino acid substitutions were identified. Full mitochondrial genomes were
extracted from the sequencing data for each isolate, and these are compared against a panel of polymorphic sites derived
from published or unpublished but publicly available data. Finally, genome-wide analysis of clone multiplicity was
performed, and the number of infecting parasite clones estimated for each isolate. Each patient harboured at least 3 clones
of P. falciparum by this analysis, consistent with results obtained with conventional PCR analysis of polymorphic merozoite
antigen loci. We conclude that genome sequencing of peripheral blood P. falciparum taken directly from malaria patients
provides high quality data useful for drug resistance studies, genomic structural analyses and population genetics, and also
robustly represents clonal multiplicity.
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Introduction
Naturally acquired blood-stage infections of the malaria parasite
Plasmodium falciparum typically harbour multiple haploid clones.
Different parasite clones may vary significantly in immunogenicity,
immune-avoidance mechanisms, susceptibility to drugs, and
transmissibility by different Anopheles mosquito vector species [1–
3]. The polyclonality and diversity of malarial infections together
present a major barrier to vaccine development [4,5]. The dif-
ferent parasite genotypes present in a single infection can be
identified by analysis of polymorphic genetic loci, such as the
merozoite surface protein genes msp1 and msp2, amplified from
peripheral blood samples of infected individuals [3,6]. The
apparent number of clones observed in any single infection thus
depends on the diversity [in that individual) of the polymorphic
marker used for the analysis, and the relative abundance of rare
clones, which often fail to be detected among PCR products
derived from numerically dominant clones. However, minority
clones are of clinical interest as they may harbour genes conferring
drug resistance and thus be selected by treatment, causing
therapeutic failure [7,8], or express antigenic variants unaffected
by vaccine-elicited immunity [9].
Studies of the multiplicity of malarial infections have examined
associations with the course and severity of infection, drug sen-
sitivity, age, geographic origin, gametocyte production and in-
fectivity to mosquitoes [10–19]. However, the most frequent
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application of clone analysis in malaria infections is in so-called
‘‘PCR correction’’ of recurrent infections in clinical trials of anti-
malarial therapy. This can be confounded by the selective
emergence after antimalarial treatment of minority clones in the
pre-treatment parasite population [20]. Commonly used PCR
methods share the limitation that such minority clones are under-
represented or may be absent among assay products. This leads to
mis-classification of PCR data in clinical trials, and underestima-
tion of the extent of allelic polymorphism in any given infection
[8,21–24].
An alternative approach to investigating polyclonality in P.
falciparum infections is adaptation of patient isolates to culture, and
use of cloning and molecular genotyping techniques to analyse
multiplicity in vitro. However, a recent study by Nsobya et al. [25],
using isolates from Ugandan malaria patients propagated in vitro,
demonstrated that there are significant inter-genotype differences
in the ability to survive in even short-term cultures, leading to a
rapid skewing of the parasite population in vitro, and an overall loss
of complexity. Thus techniques which avoid expansion of parasite
material, whether by polymerase chain reaction or by in vitro
expansion, are more likely to preserve the complexity and relative
abundance of different genotypes in patient isolates of interest.
The recent development of new generation direct sequencing
technologies, capable of elucidating whole-genome data from
relatively small biological samples, provides a potential new
approach to investigate polyclonality in malaria infections. These
technologies fractionate DNA samples into random end-tagged
fragments of a uniform size, which are amplified in situ on a solid
matrix, and then record the sequence of base addition to each
growing amplicon. This produces a large number of short, but
‘‘massively’’ parallel sequence (MPS) reads which permit assembly
of a partial or full genome provided an established reference
genome sequence is available, and sufficient depth (number of
reads at each nucleotide position) and breadth (proportion of the
genome amplified and sequenced) of coverage are achieved. The
single molecule sequencing approach of MPS technologies ensures
that each sequence read (or pair of sequence reads if both ends of
the molecule are sequenced) is essentially a haplotype, providing
great scope for the characterisation of polyclonal infections. Using
MPS, it is now possible to derive genome sequence data from a
small volume of material from any organism of interest. Although
assembly of extended genomic sequences is facilitated by the use of
existing reference sequence, de novo or reference-free approaches
are becoming more widely used [26]. MPS is now being assessed
as a method to examine genome-wide polymorphism in P.
falciparum, using both parasites cultured in vitro and material taken
directly from the peripheral blood of people infected with the
parasite [27]. However, the AT-rich genome of malaria parasites
poses particular challenges for this approach to genome assembly
[28], and thus it is unclear how well MPS will perform in analysis
of P. falciparum taken directly from patients, particularly as natural
infections commonly carry multiple clones with distinct genotypes
at polymorphic loci.
In this study we use MPS to derive genome-level sequence data
for five P. falciparum parasite isolates prepared directly from
peripheral blood of four malaria patients, after minimal or no
amplification of the parasite genome [28]. To evaluate the fidelity
of the sequence data generated, and its utility for studies of
genomic variation, we first examined structural differences among
our isolates by global scanning for copy number variants (CNV).
We then assessed sequence diversity at known polymorphic sites
among six genes considered to be under strong selective pressure
from antimalarial therapy, and among full-length mitochondrial
sequences derived from each isolate. Finally, a genome-wide
analysis of multiplicity was performed using other loci, selected
empirically, which provided robust estimates of genotype multi-
plicity in each patient. These results were compared to con-
ventional assessments of polyclonality using polymorphic loci
encoding merozoite surface antigens.
Methods
Sample collection
Samples (OX001, OX003, OX005A, OX005B, OX006) were
collected from returning travellers attending the Hospital for
Tropical Diseases (HTD), or a referring hospital, with malaria
symptoms, who were diagnosed positive by malaria films
examined in the Department of Clinical Parasitology, and who
gave written consent to have their blood samples analysed under a
protocol approved by the University College London Hospitals
Research Ethics Committee (project ref no. 07/0055). A minimum
parasite density of 1% of infected erythrocytes was set as a cut-off
to ensure DNA preparations included a high parasite to human
white blood cell ratio.
Processing of blood samples
EDTA blood remaining after diagnosis (2–4 mL) was prepared
for genomic DNA extraction by removal of human white blood
cells within four hours of venesection. Briefly, blood was diluted
two to three-fold in phosphate-buffered saline, pH 7.2 (PBS),
layered on to a 2 ml cushion of LymphoprepH (Axis-Shield, UK),
and centrifuged for 30 minutes at 4,000 g in a bench-top
centrifuge at room temperature. Upper layers, including leuko-
cytes, were removed, and the erythrocyte pellet was washed once
in PBS and re-suspended to a total volume of 5 ml with PBS. The
erythrocyte suspension was passed once through a PlasmodipuTM
filter (Euro-Diagnostica), resuspended in 5 ml PBS and pelleted at
4000 g for 10 minutes. The erythrocyte pellet was stored frozen at
220uC, pending DNA extraction using the Qiagen DNA Blood
Maxi (Qiagen, Crawley, UK) extraction kit.
Purified DNA samples were taken to the Wellcome Trust
Sanger Institute (WTSI) malaria labs and prepared for MPS
sequencing as described elsewhere [27,28]. In parallel, each DNA
sample was analysed for multiplicity using a standard nested PCR
method to amplify polymorphic regions of pfmsp1 and pfmsp2 [6].
Amplicons were fractionated on agarose gels.
Sequence Analysis
All samples underwent whole genome sequencing on the
Illumina Genome Analyzer II platform, as previously described
[27]. Briefly, paired 54- or 76-base pair sequence reads were
generated on DNA fragments of 200–300bp. The fastq files for
each lane of sequence data for each isolate were mapped onto the
P. falciparum 3D7 reference genome V2.1.5 (ftp://ftp.sanger.ac.uk/
pub/pathogens/Plasmodium/falciparum/3D7/3D7.version2.1.5/)
using the Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.
net), resulting in bam files that can be analysed using SAMtools/
BCFtools (http://samtools.sourceforge.net). Using this toolkit, we
excluded reads of poor mapping quality, and derived a list of SNP
(and small insertions and deletions (indels)) based on uniquely
mapping reads and acceptable levels of coverage (minimum 10,
max. 2000). In addition we applied a filter to rule out error-prone
variant calls, based on a pseudo Phred Q-score, where a Q30/60
refers to one error per one-thousand/million bases. We used a
threshold Q30, and the sensitivity of the estimated total number of
SNP (and indels) to this score is shown in Table 1. Using this
approach we identified SNP in the mitochondria genome (5.97 kb),
and used tabulations of coverage across all SNP positions to call
Parasite Genomes Direct from Malaria Patients
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nucleotides. All raw sequence data (fastq format) used here are
publicly available as fastq files, and as ‘‘Open Access’’ samples (prefix
PL) on the WTSI Malaria Programme web-site [29].
Identification of copy number variation
CNV, including deletions and sequence amplifications, may be
identified using sequence coverage data. In particular, regions with
little or no coverage may be deleted in some or all genomes in the
infection, whilst those with coverage in excess of the average may
be amplified. A list of small indels from the paired end mapping
process with evidence from at least two isolates was constructed
using SAM tools with the same Q30 threshold. In particular, small
indels are detected by comparing the distance between mapped
read pairs to the average insert size of the genomic library [30,31].
For each isolate, we then calculated total coverage at positions in
the sequence that were in coding regions and were classified as
unique by sliding 50-mers across the reference genome. To further
identify regions with CNVs we adopted a similar approach to
Yoon et al. [32]. In particular, coverage data were normalised for
GC content, and a Z-score statistic calculated using 100-bp
windows by subtracting the mean of all windows and dividing by
the standard deviation. These Z-scores were converted to p-values
and we report any regions lower than a 1026 threshold. Regions of
interest were examined graphically using LookSeq software [33]
(available at http://lookseq.sanger.ac.uk/lookseq2/index.html).
Analysis of drug resistance-associated loci
Illumina nucleotide calls were extracted from genome read data
at each position for the following six loci, implicated in resistance
to artemisinins or other antimalarials: (i) pfatpase6 (PFA0310c, chr
1: 265 447-269 412); (ii) pfmrp1 (PFA0590w, chr 1: 465 875–471
344); (iii) pfmdr1 (PFE1150w, chr 5: 957 885-962 144); (iv) pfcrt
(MAL7P1.27, chr 7: 458 990–461 216); (v) pfmrp2 (PFL1410c, chr
12: 1 192 877–1 199 204); pfnhe1 (P13_0019, chr 13: 170 076–175
991). Sequence from each locus was converted to fasta format after
manual removal of introns, and compared to sequence from the
other isolates, and the 3D7 reference genome, by alignment in
Clustal W (http://www.ebi.ac.uk/Tools). At these loci, coverage
depth was typically 40 to 100 reads; multiplicity at a specific site
was often observed, indicated by more than one nucleotide being
called; a low threshold (2 calls) was set for retaining minor variants
in the analysis, irrespective of the total read coverage at that
position. Coverage breadth was excellent, being close to 100% for
each resistance-associated locus.
Genome-wide screen for minimal multiplicity
For each of our test isolates we inferred the minimal multiplicity
by considering the number of distinct haplotypes formed by
combinations of three SNP on single or paired reads. We removed
any haplotypes that had a frequency of one, and ignored those sets
of haplotypes with total frequency (coverage) less than 10, or were
located in genomic regions that were not unique (defined using 50-
mers, see above).
Results
Patients
Between December 2008 and December 2009, subjects gave
consent for genetic studies on parasite isolates derived from the
diagnostic blood samples taken as part of their routine care. Five
DNA samples from four of these volunteers were deemed suitable
for taking into the Illumina DNA sequencing pipeline. For one
patient (OX005), two sequential samples, taken at 0 hours (i.e.
pre-treatment) and 9 hours after treatment, were analysed in
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parallel. All patients were successfully treated and recovered from
malaria.
OX001. This patient was a 53-year old Ghanaian who had
lived in the UK all their adult life and presented with symptoms of
acute malaria after a visit to Accra and the surrounding
countryside for a period of six weeks. Having started to feel
unwell in Ghana, the patient reported taking one (unidentified)
tablet which was bought from a street trader, but reported no
other treatment, and did not use chemoprophylaxis.
OX003. This 26-year old Zimbabwean-born Caucasian
patient had lived in the UK for four years and reported having
malaria 3 times before moving to the UK. The patient presented
with circulating P. falciparum trophozoites and schizonts at a
parasitaemia of 1.3% following a visit to Mozambique (Mapute/
Tete) for a period of three weeks, during which no chemo-
prophylaxis or treatment was taken. A single pre-treatment blood
sample was analysed.
OX005. Following a visit to family in Ghana, this 49-year-old
Ghanaian-born UK resident (of 22 years) presented with severe
malaria and a peripheral P. falciparum parasitaemia of 3.0% (details
presented in reference 34). Two sequential samples, F54840 and
F55564, taken prior to treatment and 8 hours later (4 to 5 hours
after commencement of quinine treatment), respectively, were
analysed.
OX006. This case is also presented in detail in reference 34.
Briefly, a 39-year-old European, resident in the UK and with no
previous malaria episodes, presented with severe P. falciparum
hyperparasitaemia (39%) after returning from 10 days in Kenya.
One sample, taken approximately 2 hours after commencing
intra-venous artesunate therapy, was analysed.
Data for all isolates described are publicly available via the
MapSeq portal at the WTSI (http://www.sanger.ac.uk/MapSeq/)
and have the following Sanger identifiers within the PF14 study
folder: OX001 = PL0001, OX003 = PL0002, OX005 = PL0004,
OX006 = PL0005.
Evidence of variation in gene copy number in patient
isolates
Read coverage, sequence intervals between read pairs and GC
content were examined around loci of interest, identified as
described in Methods. Two examples of gene amplification are
presented in Figure 1, in isolates OX001 and OX006. The
richness of data clearly differs between these two isolates, as the
former was analysed using an earlier format of the MPS procedure
which utilised 54nt reads, whereas 76nt reads were used in analysis
of OX006 (Table 1; Fig. 1). The pfgch1 locus, which has previously
been identified as undergoing amplification in Southeast Asian
Figure 1. Identifying amplifications as areas of high MPS coverage. Length of sequence intervals between paired reads (nt) and coverage
(read frequency) are plotted against chromosome position and %GC content for two loci in isolates OX001 and OX006. pfgh1 displays high coverage
consistent with amplification in OX006, but not OX001. pfef2 displays high coverage consistent with amplification in OX001, but not OX006. Loci of
interest (red circles) are shown within100 km of genomic context. Red colouring within the read pile-ups signify polymorphic sites within a read in
which a non-reference allele is present (i.e. SNP).
doi:10.1371/journal.pone.0023204.g001
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parasite isolates [35], showed evidence of excess coverage in isolate
OX006, but not in isolate OX001 (Fig. 1), nor in the other 4
isolates (data not shown). The PF14_0486 locus (pfef2) encodes an
EF2 translation elongation factor related to Ef2b isoforms of
metazoan eukaryotes, with 65% amino acid sequence identity to
Drosophila melanogaster Ef2b (accession number AY075481). pfef2
displayed high coverage consistent with amplification in isolate
OX001, but not in OX006 (Fig. 1).
Evidence of deletion of genomic sequences, defined with respect
to the 3D7 reference genome sequence, was found at numerous
loci across the genome in each isolate. Figure 2 presents pile-up
graphics [33] for two isoforms of pfrbp2 encoded on chromosome
13 (MAL13P1.176; PF13_0198). The data clearly distinguish
between two previously described deletions that are common
towards the carboxy terminus of MAL13P1.176, encoding the
b-homologue of pfrbp2: OX001 and OX005 are to seen to have
Figure 2. Deletions in pfrbp2 homologues a and b appear as areas with inflated sequence intervals in four isolates. Two isoforms of
RBP2 are encoded by adjacent genes on chromosome 13, arranged head to head and transcribed in opposite directions. 60 kb around these genes
are depicted, for four isolates. Loci of interest (red arrows) have either a,600 bp deletion in the carboxy-terminal serine-rich domain of homologue b
(red elipses), or a ,2–300 bp deletion in the low-complexity protein domain immediately upstream in both genes (blue elipses). Y-axis depicts
sequence interval between paired reads. X-axis depicts nucleotide coordinates along the chromosome, as in Figure 1.
doi:10.1371/journal.pone.0023204.g002
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apparent read intervals of ,950nt over this domain, which is
approximately 600 bp longer than the average read length in that
chromosome region (Fig. 2). This fits well with the expected
587 bp deletion in the serine-rich domain, which was recently
shown to be common across Africa [35]. In contrast, OX003 and
OX004 show evidence of a smaller deletion in the low complexity
domain immediately upstream of the serine-rich region. Interest-
ingly, this is also seen at the C-terminus of the a-homologue
(PF13_0198), which lacks the serine-rich domain and does not
exhibit the deletion-polymorphism characteristic of the adjacent b-
homologue. Among other loci displaying similar evidence of intra-
genic deletion in one or more of our clinical isolates was the
conserved Plasmodium protein (unknown function) PF14_0226 in
which the 12 amino acid repeat motif S(or K or W)TLKEK-
KNEMNV occurs in 7 tandem repeats in 3D7, but typically
occurred as 2 to 5 repeats in MPS-derived genome sequences
from our isolates. Verification that this observation is not due to
ambiguous assembly of repeats could be accomplished simply by
amplification and sequencing of this region of the gene.
Of particular note was occasional evidence of larger chromo-
somal deletions, such as that encompassing one or both of the
loci encoding Rh1/Clag3.1 and Rh1/Clag3.2 (PF0110w and
PF0120w) at the left end of chromosome 3. In isolates OX005 and
OX005A, both genes and the chromosomal region between them
appeared to be deleted, totalling over 20 kb of missing chromo-
some sequence compared to the reference. This is consistent with
reports of variation in the size of this chromosome estimated using
pulse-field gel electrophoresis, with 3D7 carrying a larger 3rd
chromosome than other isolates tested in one study [36]. Thus the
duplication of the clag3 locus described in laboratory lines [37] was
Figure 3. Evidence of a major deletion at the right end of chromosome 3 in isolate OX005. Paired reads across the whole of chromosome
3 are presented in pile-up view for two isolates, OX005 and OX006 (upper panel). Y-axis depicts sequence interval between paired reads, and X-axis
gives chromosome coordinates as in Figures 1 and 2. A detailed view of,70 kb around the clag3.2 and clag3.1 loci is also shown for 4 isolates (lower
panel). The locus between PFC0110w and PFC0120w is a degenerate var gene lacking a full-length ORF in 3D7 and other parasite sequences in the
available databases.
doi:10.1371/journal.pone.0023204.g003
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not readily identified in MPS sequence data of our wild isolates.
Interestingly, the PfEMP1 pseudogene between the two clag3 loci
in 3D7 was identified by MPS in some, but not all of our isolates
(Fig. 3).
Sequence polymorphism in known loci under drug
selection
In order to evaluate the potential of MPS analysis using para-
site material taken directly from treated malaria patients for
phenotype-genotype association studies, we derived full length
data for 6 loci known or considered likely to be under selective
pressure from antimalarial drugs (see Methods). Data for all 5
isolates and all 6 loci are presented in Table 2. In each of these
genes, known polymorphisms were identified. Both the reference
and variant alleles were present in at least one gene from each of
the isolates OX001, OX003 and OX006. This indicates that these
were polyclonal infections, and that multiple alleles of these genes
were present. Both isolates from patient OX005 appeared
monoclonal (and identical) at these loci, except for apparent
polyclonality in the repetitive ‘‘hinge’’ region of pfmdr1 and in a
three amino-acid repeat region of pfmrp2. In both loci, this may
conceivably be caused by ambiguous assembly of highly-repetitive
sequences, but we cannot rule out true polyclonality in both these
isolates (see further analysis below).
Recent data suggest that the two amino acid changes in the P.
falciparum ABC transporter MRP1 observed in isolate OX006 are
associated with artemisinin and anti-folate resistance in African
studies [38,39], and it is possible that the response to artesunate-
treatment of the parasites in this individual may have been delayed
[34]. Examination of the pfmrp1 sequence at codon 876 in later
follow-up blood samples from this patient may be instructive, as
this locus exhibited mixed wild-type and mutant alleles in the
immediately post-treatment sample analysed here. The data
presented on pfmrp2 represents the first full-length analyses of this
gene in wild parasites; 8 non-synonymous codons were found in
addition to the amino-acid repeat polymorphism at codons 235,
240 and 242. In pfmdr1, which encodes the best characterised
transporter protein in P. falciparum, PgH1, we encountered the
expected polymorphisms at codons 86, 184, 649–654 and 1246.
Unexpectedly, our Mozambique isolate also harboured a novel
non-synonymous substitution, T496I. This region of the locus is
not usually analysed in sequencing studies, and there are no data
to suggest whether or not this substitution is relevant to parasite
responses to antimalarial treatment.
The less stringent call threshold for SNP used in our analysis of
drug-resistance associated loci permitted identification of low
frequency amino acid variants at expected positions: for example
in the pfmdr1 locus of isolate OX001 at codon 86 there were 46
MPS ‘‘calls’’ for T at nucleotide 256, encoding the resistance-
associated tyrosine at this position, and 6 calls for the wild-type
nucleotide A, encoding asparagine. Similarly, at codon 1246 there
were 42 calls for T at nucleotide 3756, encoding a resistance-
associated tyrosine, and 4 calls for G, encoding aspartic acid.
Thus, as these low frequency calls generated sequences consistent
with previous studies of the locus, we conclude that they are bona
fide results, and so caution should be exercised in setting high call
thresholds in MPS studies of potentially polyclonal P. falciparum
isolates. This approach also readily identified substitutions of
interest in the pfdhfr (PFD0830w) and pfdhps (PF08_0095) loci
which are known to modulate parasite sensitivity to the anti-folate
drugs (Table 3). All isolates harboured the ‘‘triple mutant’’
haplotype IRNI at codons 51, 59, 108 and 164 of pfdhfr, but
three different haplotypes of pfdhps were seen. Only the Kenyan
isolate OX006 harboured the pfdhps 540E mutation associated
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with high rates of treatment failure with sulphadoxine-pyrametha-
mine, and known to be much more common among travellers
returning with malaria from east Africa [40].
In summary, specific analysis from our MPS data of a series of
loci implicated in drug response identified expected polymor-
phisms in each gene, strongly suggested polyclonality in most if not
all isolates, and suggested setting of low call thresholds can assist in
identifying low abundance sequences. The analysis identified
previously unknown substitutions in pfmdr1 and pfmrp2 that now
require evaluation as possible markers of parasite response to
antimalarial drugs.
Polymorphism in mitochondrial genome sequences
Polymorphic sites in the 5.97 kb mitochondrial genome were
derived for each sample by the identification of nucleotides that
differed to the reference sequence. As expected the mitochondria
had at least ten-fold more coverage than the nuclear genome
(Table 1). The full mitochondrial sequence was generated for each
patient isolate, and compared against the panel of 32 polymorphic
sites by Joy et al. [41] (Table 3). The parasite isolates were in each
case almost identical to the reference sequence. Three polymor-
phisms were found, and two corresponded to sites previously
identified by Joy and colleagues. These results indicate that MPS
sequencing data derived from uncloned and uncultured parasite
material is of a sufficiently high quality for use in phylogenetic
studies based on variation in the parasite mitochondrial genome.
Clonal multiplicity estimated from conventional pfmsp2
genotyping
Nested PCR analysis of the pfmsp1 and pfmsp2 locus was
undertaken to estimate the polyclonality of each isolate using
conventional methods. The results are presented in Table 4. All
isolates except OX005A harboured polyclonal infections as
evidenced by analysis of pfmsp1 and pfmsp2 alleles, with five, four,
one, two and six distinct alleles, respectively. It was observed that
isolate OX005B, taken 9 hours after initiation of quinine therapy,
harboured an additional P. falciparum genotype not present in
isolate OX005A, taken prior to the first dose.
Genome-wide multiplicity from MPS data
Multiplicity was estimated only for loci in which 3 single-
nucleotide polymorphisms (SNP) occurred in close proximity,
using two different approaches. The first analysis identified loci
where three SNP were found on a single read of 54 or 76 bp
(Table 1). In the second analysis, tri-SNP loci were deployed in
which one of the SNP occurred on an independent sequence read
adjacent to the read with the other two SNP (a "2+1’’ SNP trio).
This latter approach could be seen as potentially the more robust,
as false 3-SNP haplotypes are less likely to be generated by errors
in two adjacent reads, than in a single poor quality sequence read.
The first analysis identified 139 polymorphic tri-SNP loci that
indicated a multiplicity of 5 genotypes or more across the whole
genome in at least one isolate. The majority of these loci did not
map to annotated genes in the reference genome, and very few loci
displayed high apparent multiplicity in more than one isolate.
However, there were clusters of adjacent loci in the same isolate
giving high multiplicity estimates, and these suggest the methods
deployed were correctly identifying highly polymorphic genomic
regions. In the second more stringent analysis, using ‘‘2+1’’ SNP
trios across paired reads, 52 tri-SNP haplotypes were identified.
Multiplicity estimates derived from both methods are compared to
those derived from PCR data in Table 5.
Estimates of clonal multiplicity derived from MPS analysis were
similar, but slightly higher than those obtained from analysis of
msp1 and msp2 alleles by PCR. Therefore, we examined the data
for evidence that the same loci were generating high multiplicity
estimates in more than one isolate, and thus might be generally
useful tools for clonal multiplicity studies, and also looked for
overlap between the two methods used. Two highly repetitive loci
contributed to elevated estimates of multiplicity in more than one
isolate, but these were only seen when using the first (less stringent)
method. The first of these, on chromosome 7, lies in the distal sub-
telomeric repeat region, and thus is unlikely to provide an accurate
estimate of clone multiplicity. The second locus, within the gene
P10_0265, which encodes a conserved Plasmodium protein of
unknown function, is within a region of open reading frame that is
highly repetitive. A tri-nucleotide repeat (CAA/CAG) occurs 67
times in the 3D7 reference sequence, encoding an extensive poly-
glutamine tract. Analysis of read-length at this locus [33] con-
firmed apparent high multiplicity around these repeat sequences
in each isolate, but it is likely this is the result of mapping
inconsistencies due to repeat overlaps. (Confirmation of the utility
of this locus for estimating multiplicity would require empirical size
comparison of appropriate PCR amplicons from different isolates.)
These findings support the use of the more stringent ‘‘2+1’’ SNP
trio approach for identification of multiplicity at polymorphic loci.
Table 3. SNP and inferred haplotypes in pfdhfr and pfdhps loci.
Isolate ID
Chromosome coordinate Gene ID OX001 OX003 OX005A OX005B OX006
MAL4:755220 PFD0830w T T T T T
MAL4:755243 PFD0830w C C C C C
MAL4:755391 PFD0830w A A A A A
MAL4:755558 PFD0830w A A A A A
DHFR haplotype codons 51_59_108_164 IRNI IRNI IRNI IRNI IRNI
MAL8:550802 PF08_0095 T T G G T
MAL8:550806 PF08_0095 G G G G G
MAL8:551114 PF08_0095 A G A A G
MAL8:551238 PF08_0095 C C C C C
DHPS haplotype codons 436_437_540_581 SGKA SGKA AGKA AGKA SGEA
doi:10.1371/journal.pone.0023204.t003
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Discussion
In this study, we have demonstrated that MPS analysis of the
genomes of P. falciparum parasites isolated directly from infected
malaria patients generates high quality data that can be used to
identify known and unknown polymorphisms in loci of interest. In
particular we demonstrated the utility of this approach to identify
genomic sites where both previously described and novel CNV
occurred. We were also able to elucidate, directly from MPS data,
drug-resistance associated haplotypes of candidate loci, and suc-
ceeded in generating high quality mitochondrial genome sequence
data suitable for phylogenetic studies. Some of the polymorphisms
identified in drug resistance-associated loci and mitochondrial
genomes have been previously described, but others were
identified here for the first time and can now be investigated in
more detail.
The main objective of the study was to investigate the utility of
MPS analysis for estimating polyclonality in natural parasite
isolates, as accurate estimation of clone multiplicity is important
for studies of drug efficacy and parasite population diversity [42,43].
Using a genome-wide approach, reproducible estimates of clonal
multiplicity in our clinical isolates were obtained, and these were
similar to estimates of clonal multiplicity estimated by standard
methods based on well-characterised size and sequence polymor-
phisms in the pfmsp1 and pfmsp2 genes. Thus we have confirmed by
two completely independent methods a high multiplicity in all of our
patients. Multiplicity was also seen in our analysis of drug resistance-
associated loci, but as expected of loci under strong directional
selection, in each case only two alleles at each position were
observed, reflecting lower overall diversity in these genes.
How does a traveller, in many cases only briefly exposed to
malaria infection risk, come to harbour multiple parasite clones?
Previous studies have quantified the risk to be one P. falciparum
infection per 1.366105 UK traveller weeks in an endemic area.
This suggests the probability of a single individual receiving more
than one infective bite per week is approximately one in one
hundred thousand [44,45]. However, as these studies were based
on Thai data, it is likely multiple inoculations are more likely in the
African locations where our patients acquired their P. falciparum
infections: the precise chance that an individual received multiple
inoculations will differ depending on the endemicity of infection in
the area visited, microheterogeneity in mosquito biting and
infection rates, use of and adherence to bite prevention and
chemoprophylaxis and the fact that multiple areas of differing risk
may have been visited by the same traveller [13]. Nevertheless, the
likelihood is that in most imported cases of P. falciparum infection,
the entire clonal repertoire entered the host in a single bite. Thus
our patients’ genetically complex parasite infections are expected
to reflect the complexity circulating in endemic area human
populations; further, as mixed gametocyte genotypes have been
shown to circulate in African studies [46,47], recombinant zygotes,
heterozygous at polymorphic loci, are expected to be common.
Thus an infection with multiplicity 6 must be the product of
at least 3 genetically unrelated oocysts, each of which was
heterozygous. This oocyst diversity could have built up in the
mosquito over a few days as, once infected, mosquitoes are known
to continue feeding on subsequent nights [48]. A single female
Anopheles may thus have several developing oocysts at slightly
different stages of maturity. This would imply that each sporozoite
inoculum may be presenting in a single event the progeny of
several blood meals in which the mosquito was infected with a
variety of parasite genotypes.
MPS data are well suited to long-range investigation of copy
number variations in both coding and non-coding genomic DNA.
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Using tools freely available on-line at the WTSI, we were able to
identify in our MPS data, almost to the exact base-pair, a
previously described 587 bp deletion in the b-homologue of pfrbp2
[49]. The evidence for genomic amplification of pfef2 (PF14_0486)
in OX001 is of interest. Although this nuclear locus encodes a
eukaryotic-type cytoplasmic translation elongation factor similar to
those of Drosophila, prokaryotic-type EF genes in the Plasmodium
apicoplast genome encode a group of proteins known to be the
parasite targets of antibacterial drugs such as clindamycin and
doxycycline [50]. It is unknown whether amplification of cyto-
plasmic elongation factor genes such as pfef2 might play a role in
parasite drug responses.
An unexpected finding was the evidence suggesting two
rhopH1/clag3 genes on chromosome 3, and the var pseudo gene
located between them, were deleted in one of our isolates. Paired
read data from other isolates was also suggestive of partial or full
deletion of the clag sequences. A possible explanation for this is
that mistakes in the assembly of MPS end-reads were made due to
the fact that these genes belong to a multi-gene family dispersed
across the genome at several loci. However, large areas of null read
coverage were not common in our dataset, and other members of
the clag gene family on chromosomes 2, 7 and 9 were examined
and displayed similar or better read coverage than their immediate
genomic context. Further alignment of GENBANK sequences for
clag3.1 and clag3.2 loci from 3D7, FVO and 7G8 laboratory
strains demonstrated remarkable conservation (.90% sequence
identity at nucleotide level) among these loci. Therefore, extreme
polymorphism at these loci is an unlikely explanation for poor read
coverage. Given the observations of Kemp et al. that chromosome
3 can vary significantly in size on pulse-field electrophoresis [36]
and the evidence of mutually exclusive expression of clag3.1 and
clag3.2 proteins in different cultured lines derived from 3D7,
suggesting functional redundancy [37], our data may be inter-
preted as a demonstration that P. falciparum can propagate per-
fectly well in vivo without one or both of the clag loci on
chromosome 3. Unfortunately, genomic material from our
patients was not prepared in such a way as to permit whole
chromosome preparations for analysis on pulse-field electropho-
resis, in order to verify this interpretation.
Concluding remarks
This study provides proof-of-principle that MPS data from
material obtained directly from malaria-infected Homo sapiens is
suitable for a variety of genomic, phylogenetic, parasitological and
clinical analyses. A great strength of MPS in general is the prospect
of high-throughput analysis of a large number of genomes in
parallel [27]; we have only examined a handful of genomes, and
thus have not taken advantage of this aspect of the technology.
However, an important feature of our analysis is that we have used
well characterised clinical material with follow-up post-treatment
DNA samples available, permitting further studies of any locus of
interest identified in the pre-treatment isolate. Thus, we have been
able to compare the pre-treatment genome sequence, for one of
our patients, with the sequence of an isolate taken after 9 hours of
antimalarial treatment. It follows that, in some settings, genomic-
level follow-up studies of drug selection signals are eminently
feasible.
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